European Orthopedic Biomaterial Market Continues To Attract Competitors Despite Economic Concerns Favorable Demographics and High-Growth Segments Will Drive Overall Market, According to Millennium Research Group
TORONTO, Oct. 22, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the European orthopedic biomaterial market will sustain moderate growth through 2022 due primarily to favorable demographics. Although both the bone graft substitute (BGS) and hyaluronic acid (HA) viscosupplementation markets will rise, expansion will continue to be negatively impacted by the ongoing economic difficulties in the region. This will have a slightly stronger impact in the market for HA viscosupplementation due to the elective nature of these procedures.
Although market expansion will not be substantial through 2022, the European orthopedic biomaterial market continues to generate interest from competitors, particularly in segments that are undergoing higher growth. For example, demineralized bone matrices (DBMs) and synthetic BGS are currently experiencing strong adoption in Europe, while demand for single-injection HA viscosupplementation products is also rising at a rapid pace.
As a result, a number of competitors are entering the orthopedic biomaterial market or attempting to expand their product portfolios through mergers and acquisitions in order to capture revenues in these higher-growth areas. For example, Wright Medical Technology purchased BioMimetic Therapeutics in November 2012, while RTI Biologics bought Pioneer Surgical Technology in July 2013. Johnson & Johnson's headline-grabbing acquisition of Synthes in mid-2012 also provided a boost for the company in this market due to Synthes' strong DBM and first-generation synthetic BGS portfolio.
"Although there is demand for premium products, the higher price of these products remains a market limiter, especially given declining health care facility budgets and falling reimbursement rates" said MRG Lead Analyst Deanna Edmunds. "Nonetheless, unlike many medical device markets in Europe, the orthopedic biomaterial market will rise, even in the short term while the economy remains unstable. Therefore, it will remain attractive to competitors, spurring innovation and the continued adoption of premium products."
Millennium Research Group's European Markets for Orthopedic Biomaterials 2014 report includes unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for BGS and HA viscosupplementation in France, Germany, Italy, Spain and the United Kingdom. Supplemental country coverage is also available for Austria, Belgium, the Czech Republic, Denmark, Finland, Greece, Hungary, the Netherlands, Norway, Poland, Portugal, Romania, Sweden, Switzerland and Ukraine, as well as in aggregate for the rest of the European countries.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
SOURCE Millennium Research Group